Dr. Rozenblit is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cedar St
New Haven, CT 06510Phone+1 203-688-4242
Education & Training
New York University School of MedicineResidency, 2015 - 2018
Icahn School of Medicine at Mount SinaiClass of 2015
Certifications & Licensure
CT State Medical License 2018 - 2026
NY State Medical License 2016 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 6 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01 - 2 citationsDatopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda
Nature Medicine. 2024-12-01 - Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history.Mariya Rozenblit, Tao Qing, Yixuan Ye, Hongyu Zhao, Erin Hofstatter
Breast Cancer Research and Treatment. 2024-11-27
Press Mentions
Breast Cancer Rates Climb Among Younger WomenJanuary 16th, 2025- Can Tumor Mutational Burden Guide Treatment in Metastatic Breast Cancer?December 27th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
